The escalating trade war between Washington and Beijing dominated discussions at the G-7 gathering in France.Politicsread more
The latest round of tariff announcements in the last few days means that by the end of the year, essentially all Chinese goods exported to the U.S. will be subject to duties.China Economyread more
Futures fell after Trump said the U.S. will raise tariffs on more than $500 billion worth of Chinese imports, increasing trade tensions.Marketsread more
Tensions stemming from the U.S.-China trade war escalated sharply over the last few days, with much happening as Asian markets were shut down for the weekend.China Economyread more
Clouding the G-7 gathering, which represents the world's major industrial economies, are the tit-for-tat tariffs between Washington and Beijing.Politicsread more
Neither the U.S. nor China wants to be seen as the party that derailed trade talks, says William Reinsch of Center for Strategic and International Studies.World Economyread more
China said Friday it will be resuming 25% duties on U.S. autos, and a further 5% on auto parts and components.Asia Marketsread more
World leaders, environmental groups and celebrities have publicly decried the vast swaths of forest being destroyed by the fires.World Newsread more
Education Minister Ong Ye Kung says the Singapore government has been preparing for the challenge of an aging workforce "for the past 20 years."Employmentread more
Megvii is known for its facial recognition technology and while revenue grew over 350% in 2018, its losses have widened.Technologyread more
Stocks in Asia fell Monday afternoon following an escalation in the U.S.-China trade war late last week.Asia Marketsread more
(Adds details, comment and background)
PARIS, Aug 6 (Reuters) - The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won regulatory approval in Europe for moderate-to-severe cases of eczema in adolescents, the companies said.
The European Commission has extended the marketing authorisation for Dupixent in the European Union to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy, Sanofi and Regeneron said in a joint statement on Tuesday.
Atopic dermatitis, more commonly known as eczema, often leads to skin irritations.
Dupixent is an important driver of growth for both Sanofi and Regeneron, given the competition on Regeneron's flagship eye drug Eylea and pressures on Sanofi's diabetes business.
"Adolescents with moderate-to-severe atopic dermatitis in the EU now have an approved biologic medicine that can significantly control persistent, debilitating symptoms such as itch and skin lesions, as well as improve sleep, which is particularly critical during these formative years," said George Yancopoulos, chief scientific officer, Regeneron.
Last month, Sanofi reported a surge in Dupixent's sales as the company posted strong second-quarter results.
The EU's latest approval for Dupixent also comes after the U.S. Food & Drug Administration (FDA) regulator in June approved Dupixent to treat nasal polyps. (Reporting by Sudip Kar-Gupta; editing by Gopakumar Warrier and Sherry Jacob-Phillips)